<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721939</url>
  </required_header>
  <id_info>
    <org_study_id>BELONG Study</org_study_id>
    <nct_id>NCT03721939</nct_id>
  </id_info>
  <brief_title>BEnefit of Arterial Preparation by LONGitudinal Scoring</brief_title>
  <acronym>BELONG</acronym>
  <official_title>BEnefit of Arterial Preparation by LONGitudinal Scoring Before Paclitaxel Eluting Balloon Angioplasty of the Superficial Femoral and Popliteal Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VentureMed Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VentureMed Group Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the artery preparation concept is to perform regular longitudinal
      micro-incisions on the inner side of the artery (&quot;scoring&quot;) and therefore promote a regular
      expansion of atheroma by balloon inflation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of clinically driven target lesion revascularization (CDTLR) at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of death from cardiovascular origin</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of major amputation of target limb</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency of the treated lesion (defined by PSVR ≤ 2.5 at duplex scan)</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of CDTLR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of major amputation</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ankle brachial index (ABI)</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford class of symptom</measure>
    <time_frame>3 and 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success of the scoring procedure</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of luminal gain</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of dissection</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of stent implantation</measure>
    <time_frame>Average of 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>FLEX Scoring Catheter plus DEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLEX Scoring Catheter</intervention_name>
    <description>Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.</description>
    <arm_group_label>FLEX Scoring Catheter plus DEB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18-year-old, with symptomatic lower extremity occlusive arterial disease

          -  Rutherford class of symptom 2 to 5

          -  Atheromatous ≥ 70 % stenosis or occlusion of SFA and/or PA

          -  Absence of &gt; 50% residual stenosis of the run-in vessels at the end of procedure

          -  Presence of at least one patent (no ≥ 50 % stenosis) run-off tibial or fibular vessel
             to the foot at the end of procedure

          -  De novo or restenotic lesions, including in-stent restenosis

          -  Willingness to participate in the study and signature of informed consent

        Exclusion Criteria:

          -  Renal failure with glomerular filtration rate (GFR) 30 ml/min or below, estimated by
             the Cockroft-Gault equation.

          -  Women who are pregnant, lactating, or planning to become pregnant during the duration
             of the study

          -  Recent artery thrombosis, at risk of distal embolization during percutaneous procedure

          -  Previous use of a PCB in the lesion during last 15 months

          -  Extremely calcified lesions, defined by calcification involving ³ 270° of the artery
             circumference over ³ 15 cm.

          -  Sub-intimal recanalization

          -  Tortuous contra-lateral femoral access with difficult cross-over

          -  Previous or planned surgery of the target lesion

          -  High risk of bleeding

          -  Contra-indication to dual antiplatelet therapy for one month, and/or to single
             antiplatelet therapy for 1 year

          -  Allergy to aspirin, clopidogrel or heparin

          -  Life expectancy less than one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Periard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fribourg Cantonal Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feeny</last_name>
    <phone>567 661 0768</phone>
    <email>kfeeny@venturemedgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Cantonal de Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Periard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Periard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rolf Engelberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 21, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

